NeuroSense Therapeutics Ltd. (NRSN) shareholders
Close on Nov 18, 2026Market cap $2.52MP/E –Yield –
Ownership
Who owns NeuroSense Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alon Ben-Noon | 3,072,600 | 19.98% | 13G (passive) amendment | Dec 31, 2023 |
| Rimon Gold Assets Ltd. Joint filing with Abir Raveh (9.99%), Goldfinger Trust (9.99%) | 2,303,729 | 9.99% | 13G (passive) | Dec 9, 2024 |
| Ariel Gordon | 1,060,561 | 6.90% | 13G (passive) amendment | Dec 31, 2023 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Alon Ben-Noon | Chief Executive Officer | 4,534,233 | Jun 17, 2026 |
| Or Eisenberg | Chief Financial Officer | 1,504,050 | Jun 17, 2026 |
| Niva Russek-Blum | Chief Technology Officer | 39,881 | Mar 30, 2026 |
| Hagit Binder | General Manager | 521,806 | Mar 30, 2026 |
| Ferenc Tracik | Chief Medical Officer | 189,618 | Mar 18, 2026 |
| Revital Mandil-Levin | Director | 52,526 | Mar 31, 2026 |
| Mark Leuchtenberger | Director | 128,000 | Mar 18, 2026 |
| Cary J. Claiborne | Director | 60,000 | Mar 18, 2026 |
| Roy Golan | Director | 60,000 | Mar 18, 2026 |
| Christine A. Pellizzari | Director | 99,898 | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alon Ben-Noon Chief Executive Officer | Jun 16, 2026 | Buy | +250,000 | $0.80 | $200.00K | 4,534,233 |
| Or Eisenberg Chief Financial Officer | Jun 16, 2026 | Buy | +250,000 | $0.80 | $200.00K | 1,504,050 |
| Or Eisenberg Chief Financial Officer | Mar 26, 2026 | Award | +200,000 | – | – | 1,254,050 |
| Niva Russek-Blum Chief Technology Officer | Mar 26, 2026 | Award | +200,000 | – | – | 467,953 |
| Hagit Binder General Manager | Mar 26, 2026 | Award | +200,000 | – | – | 521,806 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NeuroSense Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 181,403 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?